{"transactions":[{"id":905488,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":1902,"price":14.25,"value":27103.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards."}],"balance_after":3591,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":905487,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":4175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of Enanta common stock issued under a relative total stockholder return unit (\"rTSRU\") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":5493,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":905486,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:33:34.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":1318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Enanta common stock issued under performance share units (\"PSUs\") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026."}],"balance_after":1318,"source":{"system":"sec-edgar","filing":"0002064832-26-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483226000016/form4.xml","form_type":"4"}},{"id":987428,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T22:08:15.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 25, 2025)."}],"balance_after":90000,"derivative":{"exercise_price":13.66,"expiration_date":"2035-11-25","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0002064832-25-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000206483225000030/form4.xml","form_type":"4"}},{"id":1349795,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-11-27T22:10:18.000Z","date":"2024-11-27","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024)."}],"balance_after":75000,"derivative":{"exercise_price":8.83,"expiration_date":"2034-11-27","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001062993-24-019776","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324019776/form4.xml","form_type":"4"}},{"id":1532178,"issuer":{"id":5673,"kind":"organization","name":"ENANTA PHARMACEUTICALS INC"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-01T20:27:12.000Z","date":"2024-04-29","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of such option will become exercisable on April 29, 2025 (the \"Anniversary Date\"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment)."}],"balance_after":150000,"derivative":{"exercise_price":13.25,"expiration_date":"2034-04-29","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001062993-24-009175","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177648/000106299324009175/form4.xml","form_type":"4"}},{"id":1809497,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OF STAFF AND CLO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:10:26.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12690,"price":0.75,"value":9517.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":14.17,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":12690},"source":{"system":"sec-edgar","filing":"0001415889-23-012133","document":"form4-08112023_040815.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1705824/000141588923012133/form4-08112023_040815.xml","form_type":"4"}},{"id":1809496,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OF STAFF AND CLO"}}],"security":"Common Stock","published_at":"2023-08-11T16:10:26.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1925,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split"},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 412 shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the purchase periods from October 3, 2022 to August 3, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock. These transaction are exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-23-012133","document":"form4-08112023_040815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705824/000141588923012133/form4-08112023_040815.xml","form_type":"4"}},{"id":1982875,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OF STAFF AND CLO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-01T16:46:16.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as to 25% of the underlying shares of common stock on February 28, 2024, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the options are fully vested."}],"balance_after":165000,"derivative":{"exercise_price":1.09,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001415889-23-003686","document":"form4-03012023_090301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1705824/000141588923003686/form4-03012023_090301.xml","form_type":"4"}},{"id":3689143,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-23T21:19:47.000Z","date":"2019-01-18","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments."}],"balance_after":60000,"derivative":{"exercise_price":2.64,"expiration_date":"2029-01-17","underlying":"Common Stock, $0.001 par value","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001171843-19-000438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184319000438/ownership.xml","form_type":"4"}},{"id":3707808,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Common Stock","published_at":"2019-01-03T13:19:59.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":2448,"price":1.93,"value":4724.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2018 through December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":29479,"source":{"system":"sec-edgar","filing":"0001171843-19-000065","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184319000065/ownership.xml","form_type":"4"}},{"id":3874249,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Common Stock","published_at":"2018-07-03T12:20:48.000Z","date":"2018-06-29","kind":"grant","acquired":true,"shares":10000,"price":1.615,"value":16150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of January 1, 2018 through June 30, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":27031,"source":{"system":"sec-edgar","filing":"0001171843-18-004990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184318004990/ownership.xml","form_type":"4"}},{"id":4095796,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-18T22:17:39.000Z","date":"2018-01-17","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on January 17, 2018 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments."}],"balance_after":110000,"derivative":{"exercise_price":2.85,"expiration_date":"2028-01-16","underlying":"Common Stock, $0.001 par value","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001171843-18-000443","document":"f4_011818kowalsky.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184318000443/f4_011818kowalsky.xml","form_type":"4"}},{"id":4110763,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Common Stock","published_at":"2018-01-03T13:16:54.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":3934,"price":1.296,"value":5098.464,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2017 through December 31, 2017 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":17031,"source":{"system":"sec-edgar","filing":"0001171843-18-000083","document":"form4kowalsky.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184318000083/form4kowalsky.xml","form_type":"4"}},{"id":4263515,"issuer":{"id":6203,"kind":"organization","name":"Protara Therapeutics, Inc."},"owners":[{"id":66536,"kind":"person","name":"Kowalsky Matthew Paul","position":1,"cik":"0001705824","reported_name":"Kowalsky Matthew Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Legal and Secretary"}}],"security":"Common Stock","published_at":"2017-07-05T20:11:26.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":10000,"price":1.296,"value":12960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":13097,"source":{"system":"sec-edgar","filing":"0001171843-17-003953","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1359931/000117184317003953/formfour.xml","form_type":"4"}}]}